Dimerix Limited · ASX:DXB

Dimerix — Sun Biomedical — Merger or Acquisition (May 2015)

17 slides from Dimerix's merger presentation, May 13, 2015

  1. Slide 1: Acquisition of Dimerix Bioscience – A Clinical Stage Biotechnology Company

    Slide 1: Acquisition of Dimerix Bioscience – A Clinical Stage Biotechnology Company

    Acquisition of Dimerix Bioscience – A Clinical Stage Biotechnology Company Dr. Anton Uvarov Executive Director Investor Presentation 13 May 2015 1

  2. Slide 2: Important information

    Slide 2: Important information

    Important information This presentation has been prepared by Sun Biomedical Limited. (“Sun Biomedical” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information nec

  3. Slide 3: Company Overview After Acquisition and Settlement

    Slide 3: Company Overview After Acquisition and Settlement

    Company Overview After Acquisition and Settlement Corporate Overview Acquisition Breakdown ASX Code: SBN Sun Biomedical Dimerix Share Price: $0.01 Market cap: $13.2m Shares 413.6m 750m Cash: $3.5m Performance 225m Shares on issue: 1323.6m Shares Performance Shares: 225.0m Options: 111.7m Options 80.

  4. Slide 4: Dimerix Transaction Overview

    Slide 4: Dimerix Transaction Overview

    Dimerix Transaction Overview Lead program: DMX200 – Phase 2 asset for treatment of Chronic Kidney Disease ⇝ Human PoC study commenced Austin Hospital ⇝ Development program focused on fast-track to IND and orphan designation ⇝ Combination of 2 drugs with extensive human data ⇝ Patent applications in

  5. Slide 5: Dimerix Clinical and Pre-Clinical Programs

    Slide 5: Dimerix Clinical and Pre-Clinical Programs

    Dimerix Clinical and Pre-Clinical Programs ⊚ DMX-200 Phase 2 clinical program currently recruiting ⊚ Multiple pipeline opportunities with all programs going straight to Phase 2 ⊚ 2 top 10 pharma engagement for GPCR platform 5

  6. Slide 6: DMX-200: Market Need

    Slide 6: DMX-200: Market Need

    DMX-200: Market Need The total chronic kidney disease (CKD) market achieved total sales of $11 billion in 2012 (Source: Decision Resources, 2014) ⊚ Current market includes erythropoietin-stimulating agents Stage Kidney Function Prevalence, US (ESAs), phosphate binders, calcium mimetics, active 1 Nor

  7. Slide 7: DMX-200: CKD Market Segmentation

    Slide 7: DMX-200: CKD Market Segmentation

    DMX-200: CKD Market Segmentation Causes of CKD: segmented market = different regulatory and reimbursement pathways Disease Example Prevalence Diabetic Kidney Diabetes Type 1, Diabetes Type 2 34% Disease Non-diabetic Kidney Glomerular Diseases 24% Disease - Primary (unknown), AutoImmune, Infection, D

  8. Slide 8: DMX-200: Initial Focus on Nephrotic Syndrome, an Orphan Disease

    Slide 8: DMX-200: Initial Focus on Nephrotic Syndrome, an Orphan Disease

    DMX-200: Initial Focus on Nephrotic Syndrome, an Orphan Disease Nephrotic Syndrome - tiny filters in glomeruli are ⊚ Nephrotic Syndrome - non-specific disorder where “broken” causing blood proteins to escape into the kidneys are damaged; characterised by proteinuria; may urine also have hypoalbumine

  9. Slide 9: What is DMX-200?

    Slide 9: What is DMX-200?

    What is DMX-200? Source: Dimerix, PLoS One 2015 ⊚ DMX-200 is a combination of propagermanium (PPG, Chemokine Receptor 2 (CCR2) antagonist) and Irbesartan (Irb, angiotensin II receptor type 1 (AT1) antagonist). Based on strong scientific rational recently published by Dimerix in top peer-reviewed jou

  10. Slide 10: DMX-200: Strong Pre-Clinical Evidence

    Slide 10: DMX-200: Strong Pre-Clinical Evidence

    DMX-200: Strong Pre-Clinical Evidence Proteinuria in STNx rats (progressive kidney disease animal model) STNx rats developed proteinuria of a level more than an order of magnitude higher than in controls. In contrast to propagermanium (PPG) or Irbesartan (Irb) monotherapies, treatment with DMX-200 (

  11. Slide 11: DMX200 – Improves disease pathology in STNx rats

    Slide 11: DMX200 – Improves disease pathology in STNx rats

    DMX200 – Improves disease pathology in STNx rats Macrophage infiltration Podocyte numbers Source: Mayo Foundation Source: Dimerix, PLoS One 2015 Source: Dimerix, PLoS One 2015 Pathology strongly supports physiology and pharmacology 11

  12. Slide 12: DMX200 – Phase 2 Clinical Trial Status

    Slide 12: DMX200 – Phase 2 Clinical Trial Status

    DMX200 – Phase 2 Clinical Trial ⊚ Treatment of Proteinuria in CKD patients ⊚ Study design: Fixed dose combination of Irbesartan + Propagermanium ⊚ Enrolment: Up to 60 patients in two Parts ⊚ Part A: Dose escalation – Up to 5 doses x 1 month, then 2 further months at maximal dose ⊚ Part B: “Best dose

  13. Slide 13: Dimerix Bioscience – Sector Activity and Precedent Transactions

    Slide 13: Dimerix Bioscience – Sector Activity and Precedent Transactions

    Dimerix Bioscience – Sector Activity and Precedent Transactions 13

  14. Slide 14: Sector Activities

    Slide 14: Sector Activities

    Sector Activities venture funding from MVM, Clarus Ventures, Novartis Venture Fund, Takeda Ventures and the Stanley Family Foundation, Heptares has moved on to develop its unique StaR® technology platform that enables it to design drugs precisely based on a detailed understanding of the structure of

  15. Slide 15: Sector Activities

    Slide 15: Sector Activities

    Sector Activities Chemocentryx (NASDAQ: CCXI, MCap US$315M) ⊚ Biopharmaceutical company targeting chemokine receptor targets ⇝ Lead program CCX140 targeting chemokine CCR2 receptor ⇝ Phase II clinical trial for diabetic nephropathy ⇝ Dec 2014: The trial met its primary endpoint ⇝ Treatment with 5 mg

  16. Slide 16: Sector Activities

    Slide 16: Sector Activities

    Sector Activities Questcor Acquired by Mallinckrodt Pharmaceuticals – Marketing Acthar® for Proteinuria in Nephrotic Syndrome ⇝ Acthar gel (injection only, steroid). ⇝ Acthar being repositioned for new indications including applications of chronic kidney disease (proteinuria in nephrotic syndrome).

  17. Slide 17: Dimerix Key Value Drivers (0-18 months)

    Slide 17: Dimerix Key Value Drivers (0-18 months)

    Dimerix Key Value Drivers (0-18 months) i. Ethics approval for additional clinical sites ii. Australian patent for lead candidate granted iii. Fast track of the US patent under Pathway Prosecution Highway iv. First patient in Phase 2 Part A study treated v. Patients at new clinical sites recruited i

Source: Internet Archive copy of dimerix.com

More decks from Dimerix Limited

All 86 Dimerix decks